Therapy News and Research

RSS

CSI launches Diamondback Predator 360 catheter system for treatment of peripheral arterial disease

Cardiovascular Systems, Inc. has launched its second-generation product, the Diamondback Predator 360° PAD System, for the treatment of peripheral arterial disease (PAD). The new device uses the same mechanism of action as the clinically proven Diamondback 360 PAD System with improvements in the crowns and shaft for enhanced clinical performance and shorter procedure times.

4 Aug 2010

ImpactRx launches smart-phone application for physicians

ImpactRx, Inc., the pioneering force in measuring the impact of pharmaceutical promotion on the behavior of the nation's highest prescribing physicians, today announced the launch of an application for physicians that provides pharmaceutical companies with timely and actionable insight into drug therapy promotion and treatment activity. ImpactRx is leveraging the capabilities of this newly available smart-phone application by using iPhone with its longitudinal physician network.

3 Aug 2010

Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced that patient enrollment is more than 60% complete in the confirmatory Phase 3 clinical study of Probuphine for the treatment of opioid addiction, and the study is expected to complete enrollment by early fourth quarter of this year, which is almost three months ahead of schedule.

3 Aug 2010

Investigators explore legal, ethical permissibility of carrying out request specific to VAD

Patients have the right to refuse or request the withdrawal of any unwanted treatment. In an article published in the online issue of Mayo Clinic Proceedings, investigators explore the legal and ethical permissibility of carrying out such a request specific to a ventricular assist device.

3 Aug 2010

Vical second-quarter revenues decrease to $2.1 million

Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.

3 Aug 2010

DUSA Pharmaceuticals total product revenues for second-quarter 2010 increase 25% to $8.7 million

DUSA Pharmaceuticals, Inc., a dermatology company that is developing and marketing Levulan Photodynamic Therapy and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

3 Aug 2010

Massage therapy student volunteers to help Bayada Regatta

Massage therapy student volunteers from Cortiva Institute - Pennsylvania School of Massage Therapy will lend their time and skills to the Bayada Regatta, one of the first adaptive rowing competitions for athletes with disabilities, on Saturday, August 28 from 9:00 AM to 4:00 PM at St. Joseph's University Boathouse, 2200 Kelly Drive in Philadelphia.

3 Aug 2010

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Northwest Biotherapeutics, Inc. today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme ("GBM"), the most rapid and lethal type of brain cancer, were treated with NWBT's DCVax®-Brain personalized immune therapy.

3 Aug 2010

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal, shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

3 Aug 2010

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) has issued an Investigational New Drug (IND)-authorisation for clinical studies with trabedersen for patients with high-grade glioma. This authorisation entitles the company to include US-American clinics both in the phase III study SAPPHIRE and in further studies.

3 Aug 2010

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Competitive Technologies, Inc. announced that McKinney Regional Cancer Care Center, a private physician oncology practice based in McKinney, TX, is the first cancer center in Texas treating with CTT's Calmare Pain Therapy Treatment medical device. Patients suffering from pain related to cancer are being treated under the direction of medical oncologist Dennis Birenbaum, M.D.

3 Aug 2010

Rush University Medical Center first to receive Octapharma grant under anniversary program

Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

3 Aug 2010

Placebo response in Parkinson's disease treatment varies with patient expectations

Individuals with Parkinson's disease were more likely to have a neurochemical response to a placebo medication if they were told they had higher odds of receiving an active drug, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Aug 2010

Ketamine reduces depression in treatment-resistant bipolar disorder: Study

A single intravenous dose of the anesthetic agent ketamine appears to reduce symptoms of depression within 40 minutes among those with bipolar disorder who have not responded to other treatments, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Aug 2010

Study explores role of genetic influence on ulcerative colitis

Adults diagnosed with ulcerative colitis after age 50 are more likely to achieve remission from their symptoms than patients diagnosed at younger ages, even when those patients receive similar treatments, according to research at Washington University School of Medicine in St. Louis.

3 Aug 2010

BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria

BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010.

3 Aug 2010

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.

3 Aug 2010

VertiFlex enrolls 150 patients in Superion Interspinous Spacer IDE clinical trial

VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 150 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

3 Aug 2010

MBF announces sale of MSD to Water Street Healthcare Partners

MBF Healthcare Partners, L.P., a middle market healthcare focused private equity firm, announced it has sold Medical Specialties Distributors, LLC, to private equity firm Water Street Healthcare Partners.

2 Aug 2010

Therapy News and Research

CSI launches Diamondback Predator 360 catheter system for treatment of peripheral arterial disease

ImpactRx launches smart-phone application for physicians

Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction

Investigators explore legal, ethical permissibility of carrying out request specific to VAD

Vical second-quarter revenues decrease to $2.1 million

DUSA Pharmaceuticals total product revenues for second-quarter 2010 increase 25% to $8.7 million

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Massage therapy student volunteers to help Bayada Regatta

NWBT reports long-term follow-up data from DCVax-Brain immune therapy clinical trials for GBM

Toxic protein in bee venom improves liposome encapsulated drug effectiveness

Antisense Pharma receives FDA IND authorisation for clinical studies with trabedersen for high-grade glioma

MRCC deploys CTT's Calmare Pain Therapy Treatment medical device

Rush University Medical Center first to receive Octapharma grant under anniversary program

Placebo response in Parkinson's disease treatment varies with patient expectations

Ketamine reduces depression in treatment-resistant bipolar disorder: Study

Study explores role of genetic influence on ulcerative colitis

BioMarin provides update on PEG-PAL Phase 2 clinical study for phenylketonuria

Alphavirus vaccine blocks tumor growth in advanced cancer: Research

VertiFlex enrolls 150 patients in Superion Interspinous Spacer IDE clinical trial

MBF announces sale of MSD to Water Street Healthcare Partners

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News